Arrowhead Shareholders Reject Say-on-Pay at 2026 Meeting

An announcement from Arrowhead Pharmaceuticals ( (ARWR) ) is now available.

At its 2026 Annual Meeting of Stockholders on March 19, 2026, Arrowhead Pharmaceuticals shareholders voted on the election of seven directors, executive compensation, an amended and restated 2021 incentive plan, and the ratification of KPMG LLP as independent auditor for the fiscal year ending September 30, 2026. All director nominees were elected, the incentive plan and auditor ratification were approved by wide margins, but shareholders rejected the advisory Say-on-Pay proposal, signaling notable investor dissatisfaction with executive compensation practices despite overall support for the company’s governance slate.

Of the 140,010,690 shares of common stock outstanding and entitled to vote as of January 22, 2026, a total of 119,801,542 shares were present in person or by proxy at the meeting, reflecting strong shareholder participation. The failure of the Say-on-Pay proposal may prompt the board and management to reevaluate pay structures and engagement with investors, while the passage of the incentive plan and auditor ratification provides continuity for operational and financial oversight going into the 2026 fiscal year.

The most recent analyst rating on (ARWR) stock is a Buy with a $63.00 price target. To see the full list of analyst forecasts on Arrowhead Pharmaceuticals stock, see the ARWR Stock Forecast page.

Spark’s Take on ARWR Stock

According to Spark, TipRanks’ AI Analyst, ARWR is a Neutral.

The score is led by improved financial performance (profitability and strong TTM cash generation) and a constructive earnings update (approval/launch progress and strengthened funding runway). Offsetting factors are valuation (high P/E with no dividend support) and a mixed technical picture with near-term weakness versus key short-term moving averages.

To see Spark’s full report on ARWR stock, click here.

More about Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals, Inc. is a biotechnology company focused on developing RNA interference-based therapeutics. Its primary activities center on discovering and advancing drug candidates aimed at treating diseases through gene-silencing technologies, positioning the company within the innovative biopharmaceutical and precision medicine markets.

Average Trading Volume: 2,788,907

Technical Sentiment Signal: Buy

Current Market Cap: $7.98B

For detailed information about ARWR stock, go to TipRanks’ Stock Analysis page.